Tianjin Lisheng Pharmaceutical Co Ltd (002393) - Net Assets
Based on the latest financial reports, Tianjin Lisheng Pharmaceutical Co Ltd (002393) has net assets worth CN¥5.00 Billion CNY (≈ $732.14 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.92 Billion ≈ $866.46 Million USD) and total liabilities (CN¥917.85 Million ≈ $134.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002393 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.00 Billion |
| % of Total Assets | 84.5% |
| Annual Growth Rate | 14.08% |
| 5-Year Change | 11.57% |
| 10-Year Change | 61.62% |
| Growth Volatility | 105.43 |
Tianjin Lisheng Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Tianjin Lisheng Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002393 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Tianjin Lisheng Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Tianjin Lisheng Pharmaceutical Co Ltd from 2006 to 2024. For live valuation and market cap data, see Tianjin Lisheng Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.80 Billion ≈ $702.39 Million |
-2.11% |
| 2023-12-31 | CN¥4.90 Billion ≈ $717.53 Million |
+12.74% |
| 2022-12-31 | CN¥4.35 Billion ≈ $636.45 Million |
-1.39% |
| 2021-12-31 | CN¥4.41 Billion ≈ $645.40 Million |
+2.52% |
| 2020-12-31 | CN¥4.30 Billion ≈ $629.53 Million |
-2.60% |
| 2019-12-31 | CN¥4.42 Billion ≈ $646.32 Million |
+37.50% |
| 2018-12-31 | CN¥3.21 Billion ≈ $470.07 Million |
+4.31% |
| 2017-12-31 | CN¥3.08 Billion ≈ $450.66 Million |
+2.14% |
| 2016-12-31 | CN¥3.02 Billion ≈ $441.21 Million |
+1.52% |
| 2015-12-31 | CN¥2.97 Billion ≈ $434.60 Million |
+2.06% |
| 2014-12-31 | CN¥2.91 Billion ≈ $425.81 Million |
-0.48% |
| 2013-12-31 | CN¥2.92 Billion ≈ $427.86 Million |
+4.93% |
| 2012-12-31 | CN¥2.79 Billion ≈ $407.77 Million |
-0.41% |
| 2011-12-31 | CN¥2.80 Billion ≈ $409.46 Million |
+5.59% |
| 2010-12-31 | CN¥2.65 Billion ≈ $387.79 Million |
+462.80% |
| 2009-12-31 | CN¥470.87 Million ≈ $68.90 Million |
-0.82% |
| 2008-12-31 | CN¥474.77 Million ≈ $69.47 Million |
+9.84% |
| 2007-12-31 | CN¥432.23 Million ≈ $63.25 Million |
-3.62% |
| 2006-12-31 | CN¥448.45 Million ≈ $65.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tianjin Lisheng Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1143.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.46 Billion | 30.60% |
| Common Stock | CN¥257.90 Million | 5.41% |
| Other Components | CN¥3.05 Billion | 63.99% |
| Total Equity | CN¥4.77 Billion | 100.00% |
Tianjin Lisheng Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Tianjin Lisheng Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Total Energy Services Inc.
TO:TOT
|
$629.72 Million |
|
WhiteFiber, Inc. Ordinary Shares
NASDAQ:WYFI
|
$629.79 Million |
|
Thanh Thanh Cong Tay Ninh JSC
VN:SBT
|
$629.79 Million |
|
Zhewen Pictures Group Co Ltd
SHG:601599
|
$630.05 Million |
|
Holike
SHG:603898
|
$629.18 Million |
|
Thesis Gold Inc
V:TAU
|
$629.16 Million |
|
Changchun Zhiyuan New Energy Equipment Co. Ltd
SHE:300985
|
$629.10 Million |
|
Hoang Huy Investment Financial
VN:TCH
|
$628.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tianjin Lisheng Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,903,429,845 to 4,769,916,090, a change of -133,513,755 (-2.7%).
- Net income of 184,528,445 contributed positively to equity growth.
- Dividend payments of 121,029,338 reduced retained earnings.
- Share repurchases of 39,587,485 reduced equity.
- Other factors decreased equity by 157,425,377.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥184.53 Million | +3.87% |
| Dividends Paid | CN¥121.03 Million | -2.54% |
| Share Repurchases | CN¥39.59 Million | -0.83% |
| Other Changes | CN¥-157.43 Million | -3.3% |
| Total Change | CN¥- | -2.72% |
Book Value vs Market Value Analysis
This analysis compares Tianjin Lisheng Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.49x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥3.04 | CN¥16.70 | x |
| 2007-12-31 | CN¥2.94 | CN¥16.70 | x |
| 2008-12-31 | CN¥3.18 | CN¥16.70 | x |
| 2009-12-31 | CN¥3.05 | CN¥16.70 | x |
| 2010-12-31 | CN¥15.76 | CN¥16.70 | x |
| 2011-12-31 | CN¥15.31 | CN¥16.70 | x |
| 2012-12-31 | CN¥15.21 | CN¥16.70 | x |
| 2013-12-31 | CN¥16.07 | CN¥16.70 | x |
| 2014-12-31 | CN¥15.98 | CN¥16.70 | x |
| 2015-12-31 | CN¥16.38 | CN¥16.70 | x |
| 2016-12-31 | CN¥16.43 | CN¥16.70 | x |
| 2017-12-31 | CN¥16.87 | CN¥16.70 | x |
| 2018-12-31 | CN¥17.54 | CN¥16.70 | x |
| 2019-12-31 | CN¥24.21 | CN¥16.70 | x |
| 2020-12-31 | CN¥23.58 | CN¥16.70 | x |
| 2021-12-31 | CN¥24.17 | CN¥16.70 | x |
| 2022-12-31 | CN¥23.84 | CN¥16.70 | x |
| 2023-12-31 | CN¥26.70 | CN¥16.70 | x |
| 2024-12-31 | CN¥18.61 | CN¥16.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tianjin Lisheng Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.81%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.21x
- Recent ROE (3.87%) is below the historical average (10.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 23.99% | 28.68% | 0.40x | 2.07x | CN¥58.44 Million |
| 2007 | 33.00% | 33.68% | 0.45x | 2.18x | CN¥92.31 Million |
| 2008 | 30.52% | 22.28% | 0.79x | 1.72x | CN¥88.76 Million |
| 2009 | 37.07% | 25.94% | 0.68x | 2.12x | CN¥112.82 Million |
| 2010 | 7.74% | 27.56% | 0.27x | 1.04x | CN¥-59.35 Million |
| 2011 | 11.65% | 42.53% | 0.27x | 1.03x | CN¥45.98 Million |
| 2012 | 10.72% | 26.60% | 0.38x | 1.06x | CN¥19.93 Million |
| 2013 | 10.19% | 28.54% | 0.32x | 1.10x | CN¥5.68 Million |
| 2014 | 3.19% | 12.00% | 0.24x | 1.12x | CN¥-198.10 Million |
| 2015 | 3.85% | 14.74% | 0.23x | 1.15x | CN¥-182.78 Million |
| 2016 | 3.83% | 13.65% | 0.24x | 1.16x | CN¥-185.91 Million |
| 2017 | 3.79% | 11.35% | 0.28x | 1.20x | CN¥-191.15 Million |
| 2018 | 5.76% | 12.30% | 0.38x | 1.22x | CN¥-136.26 Million |
| 2019 | 4.26% | 11.65% | 0.31x | 1.19x | CN¥-253.55 Million |
| 2020 | 0.20% | 0.76% | 0.23x | 1.17x | CN¥-421.59 Million |
| 2021 | 2.77% | 11.18% | 0.21x | 1.18x | CN¥-318.95 Million |
| 2022 | 2.15% | 8.16% | 0.22x | 1.22x | CN¥-341.33 Million |
| 2023 | 7.38% | 31.38% | 0.20x | 1.18x | CN¥-128.51 Million |
| 2024 | 3.87% | 13.81% | 0.23x | 1.21x | CN¥-292.46 Million |
Industry Comparison
This section compares Tianjin Lisheng Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tianjin Lisheng Pharmaceutical Co Ltd (002393) | CN¥5.00 Billion | 23.99% | 0.18x | $629.47 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers its products in various forms comprising tablets, capsules, granules, and injections for use in various therapeutic fields, such as nervous system, musculoskeletal, genitourinary system, antineoplastic and immune system, … Read more